This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baden, L. R.
Right arrow Articles by Eliopoulos, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baden, L. R.
Right arrow Articles by Eliopoulos, G.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2002, p. 1160-1163, Vol. 40, No. 4
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.4.1160-1163.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Molecular Characterization of Vancomycin-Resistant Enterococci Repopulating the Gastrointestinal Tract following Treatment with a Novel Glycolipodepsipeptide, Ramoplanin

L. R. Baden,1* I. A. Critchley,2 D. F. Sahm,2 W. So,3 M. Gedde,3 S. Porter,3 R. C. Moellering, Jr.,1 and G. Eliopoulos1

Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts,1 Focus Technologies, Herndon, Virginia,2 IntraBiotics Pharmaceuticals, Inc., Mountain View, California3

Received 3 October 2001/ Returned for modification 15 November 2001/ Accepted 29 December 2001

We characterized baseline and repopulating stool isolates recovered during a phase II trial of ramoplanin for the treatment of patients with stool carriage of vancomycin-resistant enterococci (VRE). Repopulation with a strain with a related genotype was found in 74, 60, and 53% of individuals in groups treated with placebo, 100 mg of ramoplanin, and 400 mg of ramoplanin, respectively. All ramoplanin-treated patients with a culture positive for VRE at day 7 had a relapse caused by a genotypically related isolate. In ramoplanin-treated patients, antibiotics with activities against anaerobic organisms were associated with positive cultures on day 7 (relative risk [RR] = 8.8; P = 0.004), and the avoidance of such antibiotics was significantly associated with culture negativity through day 21 (RR = 0.16; P = 0.02).

* Corresponding author. Mailing address: PBB-A4, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02215. Phone: (617) 732-6706. Fax: (617) 732-6829. E-mail: lbaden{at}partners.org.

Journal of Clinical Microbiology, April 2002, p. 1160-1163, Vol. 40, No. 4
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.4.1160-1163.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Freeman, J., Baines, S. D., Jabes, D., Wilcox, M. H. (2005). Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 56: 717-725 [Abstract] [Full Text]  
  • Stiefel, U., Pultz, N. J., Helfand, M. S., Donskey, C. J. (2004). Efficacy of Oral Ramoplanin for Inhibition of Intestinal Colonization by Vancomycin-Resistant Enterococci in Mice. Antimicrob. Agents Chemother. 48: 2144-2148 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»